Ä¢¹½ÊÓƵAPP

Hari is Founding President of Mirai Bio, Chief Operating Officer of Tessera Therapeutics, as well as Operating Partner at Ä¢¹½ÊÓƵAPP. At Tessera, his responsibilities span across research, manufacturing, program strategy and management and IP. Hari is a global Biopharmaceutical executive with 20+ years of value creation in the biologics and vaccine industry.

Before Flagship, Hari served as Chief Technology Officer of Spark Therapeutics, leading the technical operations, process and technology development and quality assurance organizations. At Spark, Hari was responsible for growing and scaling the company’s cutting-edge technology capabilities for an expanding development pipeline.

Prior to Spark, Hari was head of Technical Development & Manufacturing at Moderna Therapeutics. At Moderna, he built and led the technology and early manufacturing organizations that delivered on supply for more than a dozen clinical programs in a brand-new technology area. Previously, Hari held a variety of scientific and cross-functional leadership positions during 18+ years at Merck & Co in the company’s commercial, R&D and manufacturing divisions, culminating in the franchise leadership of pediatric and adult vaccines representing over $2B in revenue.

Hari has a Ph.D. in Chemical Engineering from the University of Delaware and an MBA from the Wharton School at the University of Pennsylvania. He is a Fellow of the American Chemical Society and the American Institute of Medical and Biological Engineers.